Exploring the Antimicrobial Potential of LL-37 Derivatives: Recent Developments and Challenges. — VialBase Research
The most recent and most explicit statement of LL-37's safety and practicality problems — high production cost, reduced efficacy in physiological conditions, proteolytic degradation, and significant toxicity to human cells. It frames native LL-37 as something the field is trying to engineer around, not deploy as-is.
- Narrative review of LL-37 derivatives and modification strategies — not primary or clinical data
- LL-37 exhibits broad antimicrobial efficacy but has several explicit limitations: high production costs, reduced efficacy under physiological conditions, susceptibility to proteolytic degradation, and significant toxicity to human cells
- Those limitations are the stated reason the field is pursuing systematic structural modification rather than native LL-37 itself
- The review examines structure-activity relationships underpinning LL-37's antimicrobial properties and the mechanisms of derivatives against bacterial infections, particularly effects on biofilms and cell membranes
- It surveys nanocarrier delivery systems, potential synergy between derivatives and traditional antibiotics, and assesses the status of LL-37 derivatives in clinical applications while identifying ongoing challenges
Summary
This 2025 review surveys efforts to turn LL-37 into a clinically usable antimicrobial through derivative design, and its opening framing is the most important part for anyone evaluating the native peptide. The authors state that while LL-37 exhibits broad antimicrobial efficacy, it has several limitations: high production costs, reduced efficacy under physiological conditions, susceptibility to proteolytic degradation, and significant toxicity to human cells. Those four problems are precisely why the research direction described here is systematic modification rather than clinical deployment of LL-37 itself. The review covers the various modification techniques applied to LL-37 and explores the structure-activity relationships that underpin its antimicrobial properties, then examines the benefits of LL-37 derivatives and their mechanisms of action against bacterial infections, with particular focus on effects on biofilms and cell membranes. It further reviews antimicrobial applications of the derivatives, examines nanocarrier systems for their delivery, and highlights potential synergy between derivatives and traditional antibiotics. The closing section assesses where LL-37 derivatives currently stand in clinical applications, identifies ongoing challenges, and offers perspectives on future modifications — the authors’ stated aim being to provide strategies for enhancing LL-37 derivatives and facilitating their transition from laboratory research to clinical practice, which is an explicit acknowledgment that this transition has not yet happened.
Key Findings
- LL-37 exhibits broad antimicrobial efficacy, but the review names four limitations up front: high production costs, reduced efficacy under physiological conditions, susceptibility to proteolytic degradation, and significant toxicity to human cells
- These limitations motivate the field’s focus on engineered derivatives rather than native LL-37, with recent research improving clinical potential through multiple systematic modifications
- The review maps structure-activity relationships underpinning LL-37’s antimicrobial properties and the mechanisms of derivatives against bacterial infections, especially effects on biofilms and cell membranes
- It surveys nanocarrier delivery systems for LL-37 derivatives and the potential synergy between derivatives and traditional antibiotics
- It assesses the current status of LL-37 derivatives in clinical applications and identifies ongoing challenges, framing the lab-to-clinic transition as still unfinished
Relevance to LL-37
This is the most recent and most direct statement of why native LL-37 is not a finished therapeutic, and its limitation list should be preserved verbatim rather than softened: high production costs, reduced efficacy under physiological conditions, susceptibility to proteolytic degradation, and significant toxicity to human cells. The cytotoxicity point in particular is a safety signal, not merely a manufacturing inconvenience — it is one of the reasons the research community is engineering derivatives instead of using the parent peptide. The reduced efficacy under physiological conditions is equally important context for anyone citing LL-37’s in vitro antimicrobial potency, since laboratory activity does not carry over cleanly into the body. Read alongside the trial of topical LL-37 cream for diabetic foot ulcer, which found a granulation benefit but no significant antibacterial or anti-inflammatory effect in vivo, this review supports a consistent conclusion: LL-37’s real-world behavior is substantially weaker and more problematic than its in vitro profile suggests, and it remains a research compound whose clinical translation is still an open engineering problem.
Citation
Yuan Y, Li J, Wei G, et al. Exploring the Antimicrobial Potential of LL-37 Derivatives: Recent Developments and Challenges. ACS biomaterials science & engineering. 2025;11(6):3145-3164. doi:10.1021/acsbiomaterials.4c02029.
See Also
- Parent compound: LL-37
Save 15% with code VIALBASE
VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.